BRD0209
BRD0209 is a highly selective and potent GSK3 inhibitor. BRD0209 demonstrates in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3).
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD529 |
| CAS # | 1597439-87-6 |
| Pricing | Customizable size, Inquiry |
| Synonym | BRD0209; BRD 0209; BRD-0209; |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C22H25N3O |
| Exact Mass | 347.1998 |
| Molecular Weight | 347.46 |
| Elemental Analysis | C, 76.05; H, 7.25; N, 12.09; O, 4.60 |
| IUPAC/Chemical Name | (S)-3-Cyclopropyl-4,7,7-trimethyl-4-phenyl-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]quinolin-5-one |
| InChi Key | YKPIWOGXCSQLFH-JOCHJYFZSA-N |
| InChi Code | InChI=1S/C22H25N3O/c1-21(2)11-15-17(16(26)12-21)22(3,14-7-5-4-6-8-14)18-19(13-9-10-13)24-25-20(18)23-15/h4-8,13H,9-12H2,1-3H3,(H2,23,24,25)/t22-/m1/s1 |
| SMILES Code | O=C1C2=C(NC3=NNC(C4CC4)=C3[C@]2(C)C5=CC=CC=C5)CC(C)(C)C1 |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Shelf Life | >2 years if stored properly |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |